Importance In metastatic esophagogastric adenocarcinoma (EGA), the addition of
programmed cell death 1 (PD-1) inhibitors to chemotherapy has improved outcomes in …

Background Esophagogastric adenocarcinoma (EGA) currently represents a main cause of
cancer related death. Despite an intensified treatment for locally advanced or metastatic …

The new era of immunotherapy is successfully implemented in the treatment of
metastatic/locally advanced esophagogastric adenocarcinoma (EGAC), as it has been …

Background Trastuzumab stimulates HER2-specific T cell responses and increases tumour
PD-L1 expression, and anti-PD-1 antibody can help enhance T cell-specific immunity of …

PURPOSE To develop recommendations involving targeted therapies for patients with
advanced gastroesophageal cancer. METHODS The American Society of Clinical Oncology …

Importance Dysregulation of the mesenchymal-epithelial transition (MET) signaling pathway
is associated with poor prognosis in gastroesophageal adenocarcinoma (GEC). We report …

Background Human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric
and gastroesophageal adenocarcinoma (GEA) is globally treated with chemotherapy plus …

Importance Effective treatment options are limited for patients with advanced, metastatic
esophageal cancer progressing after 2 or more lines of systemic therapy. Objective To …

Gastroesophageal adenocarcinoma (GEA) and squamous esophageal cancer (ESCC) are
responsible for> 1 million deaths annually globally. Until now, patients with metastatic GEA …

Background The addition of nivolumab to chemotherapy improves survival in patients with
advanced oesophagogastric (oesophageal, gastric, or gastro-oesophageal junction) …